Utility of Intrathecal Fluorescein in Transmastoid Repair of Temporal Encephaloceles
Annals of Otology, Rhinology & Laryngology · 2026-12 · 135 (12) · 922-928
DOI: 10.1177/00034894261470543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Otology, Rhinology & Laryngology, online erschienen am 20.07.2026. Verfasst von Keshav V Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Fluorescein, Encephalocele, Fluorescent Dyes, Temporal Lobe. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To assess the safety and efficacy of intrathecal fluorescein administration during transmastoid repair of temporal lobe encephaloceles and identify predictors for intraoperative fluorescein identification.
Methods
This was a retrospective case-control study of consecutive adult patients with temporal lobe encephaloceles repaired via transmastoid approach from October 2012 to October 2024 at a single tertiary academic medical center. Medical records of qualifying patients were searched for demographics, diagnostic workup, disease characteristics, and intraoperative and postoperative outcomes. Analysis incorporated the Wilcoxon rank-sum, Pearson’s X 2 , and Fisher’s exact tests, along with unadjusted Kaplan-Meier estimates. Outcomes included encephalocele recurrence and symptomatic resolution rates, fluorescein complications, and rates and predictors of intraoperative fluorescein identification.
Results
38 patients met inclusion criteria (age 59.8 + 11.9 years, BMI 35.8 + 8.7 kg/m 2 , 23 [60.5%] female). Recurrence (0% vs 11.5%, P = .54) and symptom resolution (83.3% vs 88.5%, P = .64) rates did not differ between patients who received and did not receive intrathecal fluorescein. No fluorescein-related complications were reported. Fluorescein was intraoperatively detected in six-twelfths cases, yielding a sensitivity of 50%. No demographic or clinical variables, including higher BMI, history of prior encephalocele, and size of largest defect, were associated with intraoperative fluorescein identification.
Conclusions
Intrathecal fluorescein administration preliminarily appears to be a safe adjunctive tool to identify the leak source in the transmastoid repair of temporal lobe encephaloceles, but its risk-benefit ratio remains up for debate. Higher-powered studies are necessary to explore its utility in specific circumstances and to determine which patients may benefit most.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Keshav V Shah, Randall James Harley
Zitieren
APA
Shah, K. V., Wong, K., Le, K., Harley, R. J., Jung, C., Hwa, T., Ruckenstein, M. J., & Bigelow, D. C. (2026). Utility of Intrathecal Fluorescein in Transmastoid Repair of Temporal Encephaloceles. Annals of Otology, Rhinology & Laryngology, 135(12), 922-928. https://doi.org/10.1177/00034894261470543
Vancouver
Shah KV, Wong K, Le K, Harley RJ, Jung C, Hwa T, et al. Utility of Intrathecal Fluorescein in Transmastoid Repair of Temporal Encephaloceles. Annals of Otology, Rhinology & Laryngology. 2026;135(12):922-928. doi:10.1177/00034894261470543
BibTeX
@article{Shah2026,
author = {Shah, Keshav V and Wong, Kevin and Le, Kim and Harley, Randall James and Jung, Christian and Hwa, Tiffany and Ruckenstein, Michael J and Bigelow, Douglas C},
title = {Utility of Intrathecal Fluorescein in Transmastoid Repair of Temporal Encephaloceles},
journal = {Annals of Otology, Rhinology & Laryngology},
year = {2026},
volume = {135},
number = {12},
pages = {922--928},
doi = {10.1177/00034894261470543}
}
EUVIMED